Company: Johnson & Johnson (Janssen)
Posted by DermRep_JNJ_7823 · March 18, 2026
Tags: launch, field, strategy
"icotyde for appropriate new patients, tremfya remains excellent" is not a strategy its a dodge going into derm accounts tomorrow and winging it.
on a $5B launch.
great.
12 upvotes · 5 comments